Interleukin 6 inhibits HBV entry through NTCP down regulation

Area of Science:

• Hepatology
• Virology
• Molecular Biology

Background:

• Hepatitis B virus (HBV) infection poses a significant global health challenge.
• The sodium-taurocholate cotransporting polypeptide (NTCP) is a crucial receptor for HBV entry into liver cells.
• Interleukin-6 (IL-6) is known to regulate NTCP expression.

Purpose of the Study:

• To investigate the impact of IL-6 on HBV entry into hepatocytes.
• To elucidate the role of NTCP in IL-6-mediated inhibition of HBV infection.

Main Methods:

• Cell culture models were used to study HBV infection.
• IL-6 treatment was applied to cells expressing NTCP.
• HBV entry, HBsAg secretion, intracellular cccDNA levels, NTCP mRNA, and NTCP-mediated taurocholate uptake were quantified.

Main Results:

• IL-6 pretreatment inhibited HBV entry by up to 90%, reducing HBsAg secretion and intracellular cccDNA.
• A 98% decrease in NTCP mRNA and an 80% reduction in taurocholate uptake were observed following IL-6 treatment.
• The dose-dependence and kinetics of IL-6's effects on viral entry and NTCP function were similar.
• Restoring NTCP expression reversed the inhibitory effect of IL-6.

Conclusions:

• IL-6 markedly inhibits NTCP-mediated HBV entry.
• Downregulation of NTCP expression by IL-6 is the mechanism underlying its antiviral effect.
• Targeting the IL-6/NTCP pathway could be a therapeutic strategy against HBV.